MG
PACB icon

Marex Group’s Pacific Biosciences PACB Stock Holding History

Marex Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-118,200
Closed -$151K – 1102
2025
Q3 		$151K Buy
+118,200
New +$160K ﹤0.01% 750
2025
Q2 		– Sell
-70,804
Closed -$83.5K – 858
2025
Q1 		$83.5K Buy
+70,804
New +$109K ﹤0.01% 625

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marex Group's PACB Position: Q4 2025 in Review

Marex Group sold out of Pacific Biosciences (PACB) in Q4 2025, closing a stake of 118,200 shares — an estimated $151K sold.

Marex Group first reported a position in PACB in Q1 2025 and held it in 2 quarters. The position peaked at $151K in Q3 2025. 215 funds tracked by Wall St. Rank hold PACB as of Q4 2025.

  • Marex Group reported no remaining Pacific Biosciences position as of Q4 2025 after selling out during the quarter.
  • Marex Group sold 118,200 Pacific Biosciences shares in Q4 2025, an estimated $151K.
  • Marex Group first reported a position in Pacific Biosciences in Q1 2025 and held it in 2 quarters.
  • Marex Group's Pacific Biosciences position peaked at $151K in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2025.

Based on Marex Group's 13F filing for Q4 2025, filed 12 Feb 2026.